I am a
Home I AM A Search Login

Papers of the Week

Papers: 30 May 2020 - 5 Jun 2020

Human Studies, Pharmacology/Drug Development


2020 Jun 03

JAMA Dermatol

Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.


Silverberg JI, L Simpson E, Thyssen JP, Gooderham M, Chan G, Feeney C, Biswas P, Valdez H, DiBonaventura M, Nduaka C, Rojo R
JAMA Dermatol. 2020 Jun 03.
PMID: 32492087.


Abrocitinib, an oral, once-daily Janus kinase 1 selective inhibitor, was effective and well tolerated in a phase 3 monotherapy trial of patients with moderate-to-severe atopic dermatitis (AD).